Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient
NCT ID: NCT00752596
Last Updated: 2017-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
1 participants
INTERVENTIONAL
2005-09-30
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)
NCT00751738
A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
NCT06299826
A Study of CLR325 in Chronic Stable Heart Failure Patients.
NCT02696967
SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
NCT05233163
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
NCT01300013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
1 tablet of 125 mg/day of azimilide 2HCl, oral
Azimilide 2HCl
One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Azimilide 2HCl
One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* Is unwilling or unable to give or understand informed consent.
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Procter and Gamble Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen R Marcello, MD
Role: STUDY_DIRECTOR
Procter and Gamble
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Scottsdale, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005076
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.